Scroll Back to Top
<span>On-Demand Webinar: Systemic Mastocytosis - Insights Into A Rare Blood Disorder</span>
March 25, 2025

On-Demand Webinar: Systemic Mastocytosis - Insights Into A Rare Blood Disorder

Presented by guest speaker Dr. Alejandro Gru, MD, Professor of Dermatology and Director of Dermapathology at Columbia University’s Irving Medical Center, this webinar provides information about systemic mastocytosis, a rare blood disorder where abnormal mast cells (white blood cells) build up in different parts of the human body, resulting in a variety of symptoms. It is estimated that over 32,000 United States citizens could be living with this disease, and this webinar profiles what causes systemic mastocytosis, how this condition affects patients, how systemic mastocytosis can be detected and how are patients being treated for this disease.
January 23, 2025

Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258

•    A modified ProMisE algorithm was prognostic for recurrence free survival (RFS) and overall survival (OS).•    RFS seemed to be improved in patients with p53 wild type cancers who received chemoradiation in addition to chemotherapy.•    Patients who had tumors with abnormal p53 protein IHC had the worst RFS and OS compared to dMMR and p53 wild type cancers.
January 30, 2025

Fully automated extraction of high-quality total nucleic acids from FFPE specimens for comprehensive genomic profiling of solid tumors

Abstract: Comprehensive Genomic Profiling (CGP) has emerged as a progressive standard of care for the understandingclinical oncology and treatment of solid tumors (Conroy, Pabla et al. 2021). By identifying actionable mutationsthrough next-generation sequencing of solid tumors CGP enables targeted therapy decisions. Formalin-fixedparaffin-embedded tissues are notoriously difficult samples in respect to reliably extracting high-qualitynucleic acids and sufficient genetic material to meet sequencing input requirements. In this work we presentan automated solution for upstream sample processing of solid tumors to enable high throughput and scalableCGP workflows by eliminating bottlenecks and enhancing results. The Sonication STAR automated DNA and RNAmethods from FFPE Tissues was created as a collaboration between Hamilton Company, Covaris, and Labcorpand it offers the potential reduction in quantity not sufficient (QNS) samples and sequencing performance improvementsresulting in a 16 % increase in fully reported tumor profiles for patients. This automated approachoffers potential saving in workflow costs, improved efficiency, and a reduction in re-extraction and re-sequencingof tumors.